Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia

Targets and Emerging Therapies for Schizophrenia

Volumn , Issue , 2012, Pages 143-185

  Marek, Gerard J ^a   Kinon, Bruce J ^b   McKinzie, David L ^b   Schkeryantz, Jeffrey M ^b   Monn, James A ^b  

^a ABBOTT LABORATORIES   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Metabotropic glutamate 2 3 receptor agonists; Novel agents, in schizophrenia treatment; Orthosteric mGlu2 and mGlu2 receptor agonists, and SAR; Phenyltetrazolylindoles, Imidazopyridines, Oxazolidinones and SAR; SAR for PAMs of mGlu2 receptors

Indexed keywords

EID: 84876951771     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118309421.ch6     Document Type: Chapter

References (163)

1. Carlsson, A., Lindquist, M. (1963). Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh), 20, 140-144.
2. Creese, I., Burt, D.R., Snyder, S.H. (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481-483.
3. Seeman, P., Lee, T., Chau-Wong, M., Wong, K. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 261, 717-719.
4. Anis, N.A., Berry, S.C., Burton, N.R., Lodge, D. (1983). The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitations of central mammalian neurons by N-methyl-aspartate. Br J Pharmacol, 79, 565-575.
5. Wong, E.H., Kemp, J.A., Priestley, T., Knight, A.R., Woodruff, G.N., Iversen, L.L. (1986). The anticonvulsanat MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A, 83, 7104-7108.
6. Lodge, D. (2009). The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature. Neuropharmacology, 56, 6-21.
7. Luby, E.D., Cohen, B.D., Rosenbaum, G., Gottlieb, J.S., Kelly, R. (1959). Study of a new schizophrenomimetic drug - Sernyl. Arch Neurol Psychiatry, 81, 363-369.
8. Tamminga, C.A. (1998). Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol, 12, 21-36.
9. Krystal, J.H., Belger, A. (1999). Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology, 21, S143-S157.
10. Lahti, A.C., Koffel, B., LaPorte, D., Tamminga, C.A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 13, 9-19.
11. Moghaddam, B., Adams, B., Verma, A., Daly, D. (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from the NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci, 17, 2921-2927.
12. Duncan, G.E., Miyamoto, S., Leipzig, J.N., Lieberman, J.A. (1999). Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res, 843, 171-183.
13. Anand, A., Charney, D.S., Oren, D.A., Berman, R.M., Hu, X.S., Cappiello, A., Krystal, J.H. (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry, 57, 270-276.
14. Holcomb, H.H., Lahti, A.C., Medoff, D.R., Cullen, T., Tamminga, C.A. (2005). Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology, 30, 2275-2282.
15. Conn, P.J., Pin, J.P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol, 37, 205-237.
16. Schoepp, D.D., Jane, D.E., Monn, J.A. (1999). Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology, 38, 1431-1476.
17. Pin, J.P., Archer, F. (2002). The metabotropic glutamate receptors: structure, activation mechanism, and pharmacology. Curr Drug Targets CNS Neurol Disord, 1, 297-317.
18. Muto, T., Tsuchiya, D., Morikawa, K., Jingami, H. (2007). Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc Natl Acad Sci U S A, 104, 3759-3764.
19. Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., Morikawa, K. (2000). Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature, 407, 971-977.
20. Ohishi, H., Shigemoto, R., Nakanishi, S., Mizuno, N. (1993a). Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience, 53, 1009-1018.
21. Gu, G., Lorrain, D.S., Wei, H., Cole, R.L., Zhang, X., Daggett, L.P., Schaffhauser, H., Bristow, L.J., Lechner, S.M. (2008). Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition. Brain Res, 1197, 47-62.
22. Ohishi, H., Neki, A., Mizuno, N. (1997). Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody. Neurosci Res, 30, 65-82.
23. Marek, G.J., Wright, R.A., Gewirtz, J.C., Schoepp, D.D. (2001). A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. N euroscience, 105, 379-392.
24. Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P.J., Neki, A., Abe, T., Nakanishi, S., Mizuno, N. (1997). Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci, 17, 7503-7522.
25. Higgins, G.A., Ballard, T.M., Kew, J.N.C., Richards, J.G., Kemp, J.A., Adam, G., Woltering, T., Nakanishi, S., Mutel, V. (2004). Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology, 46, 907-917.
26. Ohishi, H., Shigemoto, R., Nakanishi, S., Mizuno, N. (1993b). Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol, 335, 252-266.
27. Tamaru, Y., Nomura, S., Mizuno, N., Shigemoto, R. (2001). Distribution of metabotropic glutamate receptor mGlu3 in the mouse CNS: differential location relative to pre-and postsynaptic sites. Neuroscience, 106, 481-503.
28. Corti, C., Crepaldi, L., Mion, S., Roth, A.L., Xuereb, J.H., Ferraguti, F. (2007). Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry, 62, 747-755.
29. Egan, M.F., Straub, R.E., Goldberg, T.E., Yakub, I., Callicott, J.H., Hairiri, A.R., Mattay, V.S., Bertolino, A., Hyde, T.M., Shannon-Weickert, C., AkilM, C.J., Vakkalanka, R.K., Balkissoon, R., Gibbs, R.A., Kleinman, J.E., Weinberger, D.R. (2004). Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A, 101, 12604-12609.
30. Harrison, P.J., Lyon, L., Sartorius, L.J., Burnett, P.W.J., Lane, T.A. (2008). The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol, 22, 308-322.
31. 3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology, 38, 1519-1529.
32. Schoepp, D.D., Monn, J.A. (2002). Pharmacology of Metabotropic Glutamate Receptors (in Glutamate and GABA Receptors and Transporters). New York: Taylor and Francis, Inc., pp. 151-186.
33. Palmer, E., Monaghan, D.T., Cotman, C.W. (1989). Trans-ACPD, a selective agonist of the phosphoinositide-coupled excitatory amino acid receptor. Eur J Pharmacol, 166, 585-587.
34. Desai, M.A., Conn, P.J. (1990). Selective activation of phosphoinositide hydrolysis by a rigid analogue of glutamate. Neurosci Lett, 109, 157-162.
35. Manzoni, O., Fagni, L., Pin, J.P., Rassendren, F., Poulat, F., Sladeczek, F., Bockaert, J. (1990). (trans)-1-Amino-cyclopentyl-1,3-dicarboxylate stimulates quisqualate phosphoinositide-coupled receptors but not ionotropic glutamate receptors in striatal neurons and xenopus oocytes. Mol Pharmacol, 38, 1-6.
36. Schoepp, D.D., Johnson, B.G., True, R.A., Monn, J.A. (1991a). Comparison of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD)-and 1R,3S-ACPD-stimulated brain phosphoinositide hydrolysis. Eur J Pharmacol, 207, 351-353.
37. Schoepp, D.D., Johnson, B.G., Salhoff, C.R., McDonald, J.W., Johnston, M.V. (1991b). In vitro and in vivo pharmacology of trans-and cis-(±)-1-amino-1,3-cyclopentanedicarboxylic acid: dissociation of metabotropic and ionotropic excitatory amino acid receptor effects. J Neurochem, 56, 1789-1796.
38. Tanabe, Y., Masu, M., Ishii, T., Shigemoto, R., Nakanishi, S. (1992). A family of metabotropic glutamate receptors. Neuron, 8, 169-179.
39. Tanabe, Y., Nomura, A., Masu, M., Shigemoto, R., Mizuno, N., Nakanishi, S. (1993). Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci, 13, 1372-1378.
40. Flor, P.J., Lindauer, K., Puttner, I., Rüegg, D., Lukic, S., Knöpfel, T., Kuhn, R. (1995). Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 2. Eur J Neurosci, 7, 622-629.
41. αq/i proteins: characterization of new antagonists. J Pharmacol Exp Ther, 50, 923-930.
42. Schoepp, D.D., Johnson, B.G., Monn, J.A. (1992). Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist. J Neurochem, 58, 1184-1186.
43. Cartmell, J., Curtis, A.R., Kemp, J.A., Kendall, D.A., Alexander, S.P.H. (1993). Subtypes of metabotropic excitatory amino acid receptor distinguished by stereoisomers of the rigid glutamate analogue, 1-aminocyclopentane-1,3-dicarboxylate. Neurosci Lett, 153, 107-110.
44. Schoepp, D.D., Johnson, B.G., Salhoff, C.R., Valli, M.J., Desai, M.A., Burnett, J.P., Mayne, N.G., Monn, J.A. (1995). Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate. Neuropharmacology, 34, 843-850.
45. Monn, J.A., Valli, M.J., Johnson, B.G., Salhoff, C.R., Wright, R.A., Howe, T., Bond, A., Lodge, D., Spangle, L.A., Paschal, J.W., Campbell, J.B., Griffey, K., Tizzano, J.P., Schoepp, D.D. (1996). Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase. J Med Chem, 39, 2990-3000.
46. Schoepp, D.D., Salhoff, C.R., Wright, R.A., Johnson, B.G., Burnett, J.P., Belagaje, R., Wu, S., Monn, J.A. (1996). The novel metabotropic glutamate receptor agonist 2R,4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3,5-dihydroxyphenylglycine: evidence for a synergistic interaction between group 1 and group 2 receptors. Neuropharmacology, 35, 1661-1672.
47. Kozikowski, A.P., Araldi, G.L., Tückmantel, W., Pshenichkin, S., Surina, E.J., Wroblewski, T. (1999). 1-Amino-ACPD, a partial agonist of group II metabotropic glutamate receptors with neuroprotective properties. Bioorg Med Chem Lett, 9, 1721-1726.
48. Yamanoi, K., Ohfune, Y. (1988). Syntheses of trans-and cis-α-(carboxycyclopropyl) glycines. Novel neuroinhibitory amino acids as L-glutamate analogue. Tetrahedron Lett, 29, 1181-1184.
49. Nakagawa, Y., Saitoh, K., Ishihara, T., Ishida, M., Shinozaki, H. (1990). (2S,3S,4S)-a-(Carboxycyclopropyl)glycine is a novel agonist of metabotropic glutamate receptors. Eur J Pharmacol, 184, 205-206.
50. Shimamoto, K., Ishida, M., Shinozaki, H., Ohfune, Y. (1991). Synthesis of four diastereomeric L-2-(carboxycyclopropyl)glycines. Conformationally constrained L-glutamate analogs. J Org Chem, 56, 4167-4176.
51. Hayashi, Y., Tanabe, Y., Aramori, I., Masu, M., Shimamoto, K., Ohfune, Y., Nakanishi, S. (1992). Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br J Pharmacol, 107, 539-543.
52. Brabet, I., Parmentier, M.-L., De Colle, C., Bockaert, J., Acher, F., Pin, J.-P. (1998). Comparative effect of L-CCG-I, DCG-IV and γ-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology, 37, 1043-1051.
53. Ohfune, Y., Shimamoto, K., Ishida, M., Shinozaki, H. (1993). Synthesis of L-2-(2,3-dicarboxycyclopropyl)glycines. Novel conformationally restricted glutamate analogues. Biomed Chem Lett, 3, 15-18.
54. Ishida, M., Saitoh, T., Shimamoto, K., Ohfune, Y., Shinozaki, H. (1993). A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord. Br J Pharmacol, 109, 1169-1177.
55. Wilsch, V.W., Pidoplichko, V.I., Opitz, T., Shinozaki, H., Reymann, K.G. (1994). Metabotropic glutamate receptor agonist DCG-IV as NMDA receptor agonist in immature in immature rat hippocampus. Eur J Pharmacol, 262, 287-291.
56. Uyama, Y., Ishida, M., Shinozaki, H. (1997). DCG-IV, a potent metabotropic glutamate receptor agonist, as an NMDA receptor agonist in the rat cortical slice. Brain Res, 752, 327-330.
57. Shibuya, A., Sato, A., Taguchi, T. (1998). Preparation of difluoro analogs of CCGs and their pharmacological evaluations. Bioorg Med Chem Lett, 8, 1979-1984.
58. Saitoh, T., Ishida, M., Shinozaki, H. (1998). Potentiation of DL-a-aminopimelate of the inhibitory action of a novel mGluR agonist (L-F 2 CCG-I) on monosynaptic excitation in the rat spinal cord. Br J Pharmacol, 123, 771-779.
59. Ishida, M., Saitoh, T., Nakamura, Y., Kataoka, K., Shinozaki, H. (1994). A novel metabotropic glutamate receptor agonist: (2S,1'S,2'R,3'R)-2-(2-carboxy-3-methoxymethylcyclopropyl)glycine (cis-MCG-I). Eur J Pharmacol, 268, 267-270.
60. Ishida, M., Saitoh, T., Tsuji, K., Nakamura, Y., Kataoka, K., Shinozaki, H. (1995). Novel agonists for metabotropic glutamate receptors: trans-and cis-2-(2-carboxy-3-methoxymethylcyclopropyl)glycine (trans-and cis-MCG-I). Neuropharmacology, 34, 821-827.
61. Shimamoto, K., Ohfune, Y. (1993). Inversion of cis-substituted a-cyclopropyl acyl anion. Stereoselective entry to the synthesis of a potent metabotropic glutamate agonist, (2S,1'S,2'S)-2-(carboxycyclopropyl)glycine (L-CCG-I), and its 3 '-substituted analogues. SynLett, 919-920.
62. Collado, I., Pedregal, C., Mazon, A., Espinosa, J.F., Blanco-Urgoiti, J., Schoepp, D.D., Wright, R.A., Johnson, B.G., Kingston, A.E. (2002). (2S,1'S,2'S,3'R)-2-(2 '-Carboxy-3 '-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. J Med Chem, 45, 3619-3629.
63. Collado, I., Pedregal, C., Bueno, A.B., Marcos, A., Gonzalez, R., Blanco-Urgoiti, J., Perez-Castells, J., Schoepp, D.D., Wright, R.A., Johnson, B.G., Kingston, A.E., Moher, E.D., Hoard, D.W., Griffey, K.I., Tizzano, J.P. (2004). (2S, 1'S, 2'R, 3'R)-2-(2 '-Carboxy-3 '-hydroxymethylcyclopropyl) glycine is a highly potent group 2 and metabotropic glutamate receptor agonist with oral activity. J Med Chem, 47, 456-466.
64. Gonzalez, R., Collado, I., Lopez De Uralde, B., Marcos, A., Martin-Cabrejas, L.M., Pedregal, C., Blanco-Urgoiti, J., Perez-Castells, J., Fernandez, M.A., Andis, S.L., Johnson, B.G., Wright, R.A., Schoepp, D.D., Monn, J.A. (2005). C3 '-cis-substituted carboxycyclopropyl glycines as metabotropic glutamate 2/3 receptor agonists: synthesis and SAR studies. Bioorg Med Chem, 13, 6556-6570.
65. Pellicciari, R., Marinozzi, M., Natalini, B., Costantino, G., Luneia, R., Giogi, G., Moroni, F., Thomsen, C. (1996). Synthesis and pharmacological characterization of all sixteen stereoisomers of 2-(2 '-carboxy-3 '-phenylcyclopropyl)glycine. Focus on (2S,1'S,2'S,3'R)-2-(2 '-carboxy-3'phenylcyclopropyl)glycine, a novel and selective group II metabotropic glutamate receptors agonist. J Med Chem, 39, 2259-2269.
66. Pellicciari, R., Costantino, G., Marinozzi, M., Macchiarulo, A., Amori, L., Flor, P.J., Gasparini, F., Kuhn, R., Urwyler, S. (2001). Design, synthesis and preliminary evaluation of novel 3 '-substituted carboxycyclopropylglycines as antagonists at group 2 metabotropic glutamate receptors. Bioorg Med Chem Lett, 11, 3179-3182.
67. Monn, J.A., Valli, M.J., Massey, S.M., Wright, R.A., Salhoff, C.R., Johnson, B.G., Howe, T., Alt, C.A., Rhodes, G.A., Robey, R.L., Griffey, K.R., Tizzano, J.P., Kallman, M.J., Helton, D.R., Schoepp, D.D. (1997). Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740): a potent, selective and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem, 40, 528-537.
68. Schoepp, D.D., Johnson, B.G., Wright, R.A., Salhoff, C.R., Mayne, N.G., Wu, S., Cockerham, S.L., Burnett, J.P., Belagaje, R., Bleakman, D., Monn, J.A. (1997). LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology, 36, 1-11.
69. Monn, J.A., Valli, M.J., Massey, S.M., Hansen, M.M., Kress, T.J., Wepsiec, J.P., Harkness, A.R., Grutsch, J.L. Jr, Wright, R.A., Johnson, B.G., Andis, S.L., Kingston, A.E., Tomlinson, R., Lewis, R., Griffey, K.R., Tizzano, J.P., Schoepp, D.D. (1999). Synthesis, pharmacological characterization and molecular modeling of heterobicyclic amino acids related to LY354740: identification of LY379268 and LY389795: two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem, 42, 1027-1040.
70. Monn, J.A., Valli, M.J., Massey, S.M., Henry, S.S., Stephenson, G.A., Bures, M., Herin, M., Catlow, J., Giera, D., Wright, R.A., Johnson, B.G., Andis, S.L., Kingston, A.E., Schoepp, D.D. (2007). Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of LY389795: identification of potent, selective and orally bioavailable agonists for mGlu2/3 receptors. J Med Chem, 50, 233-240.
71. Rorick-Kehn, L.M., Johnson, B.G., Burkey, J.L., Wright, R.A., Calligaro, D.O., Marek, G.J., Nisenbaum, E.S., Catlow, J.T., Kingston, A.E., Giera, D., Herin, M.F., Monn, J.A., McKinzie, D.L., Schoepp, D.D. (2007). Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther, 321, 308-317.
72. Nakazato, A., Kumagai, T., Sakagami, K., Yoshikawa, R., Suzuki, Y., Shigeyuki, C., Ito, H., Taguchi, T., Nakanishi, S., Okuyama, S. (2000). Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J Med Chem, 43, 4893-4909.
73. Dominguez, C., Prieto, L., Valli, M.J., Massey, S.M., Bures, M., Wright, R.A., Johnson, B.G., Andis, S.L., Kingston, A., Schoepp, D.D., Monn, J.A. (2005). Methyl substitution of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist. J Med Chem, 48, 3605-3612.
74. Woltering, T.J., Adam, G., Huguenin, P., Wichmann, J., Kolczewski, S., Gatti, S., Bourson, A., Kew, J.N.C., Richards, G., Kemp, J.A., Mutel, V., Knoflach, F. (2008). Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA. ChemMedChem, 3, 323-335.
75. Nakazato, A., Sakagami, K., Yasuhara, A., Ohta, H., Yoshikawa, R., Itoh, M., Nakamura, M., Chaki, S. (2004). Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0] hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem, 47, 4570-4587.
76. Yasuhara, A., Sakagami, K., Yoshikawa, R., Chaki, S., Nakamura, M., Nakazato, A. (2006). Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists. Bioorg Med Chem, 14, 3405-3420.
77. Rudd, M.T., McCauley, J.A. (2005). Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2). Curr Top Med Chem, 5, 869-884.
78. Gasparini, F., Spooren, W. (2007). Allosteric modulators for mGlu receptors. Curr Neuropharmacol, 5, 187-194.
79. Fraley, M.E. (2009). Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat, 19, 1-17.
80. Freedman, N.J., Lefkowitz, R.J. (1996). Desensitization of G protein-coupled receptors. Recent Prog Horm Res, 51, 319-353.
81. Galici, R., Echemendia, N.G., Rodriquez, A.L., Conn, P.J. (2005). A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther, 315, 1181-1187.
82. Johnson, M.P., Baez, M., Jagdmann, G.E. Jr, Britton, T.C., Large, T.H., Callagaro, D.O., Tizzano, J.P., Monn, J.A., Schoepp, D.D. (2003). Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethyl-amine. J Med Chem, 46, 3189-3192.
83. Barda, D.A., Wang, Z.Q., Britton, T.C., Henry, S.S., Jagdmann, G.E., Coleman, D.S., Johnson, M.P., Andis, S.L., Schoepp, D.D. (2004). SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide. Bioorg Med Chem Lett, 14, 3099-3102.
84. Johnson, M.P., Barda, D., Britton, T.C., Emkey, R., Hornback, W.J., Jagdmann, G.E., McKinzie, D.L., Nisenbaum, E.S., Tizanno, J.P., Schoepp, D.D. (2005). Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). P sychopharmacology, 179, 271-283.
85. Galici, R., Jones, C.K., Hemstapat, K., Nong, Y., Echemendia, N.G., Williams, L.C., de Paulis, T., Conn, P.J. (2006). Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic-and anxiolytic-like effects in mice. J Pharmacol Exp Ther, 318, 173-185.
86. Benneyworth, M.A., Xiang, Z., Smith, R.L., Garcia, E.E., Conn, P.J., Sanders-Bush, E. (2007). A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol, 72, 477-484.
87. Pinkerton, A.B., Cube, R.V., Hutchinson, J.H., James, J.K., Gardner, M.F., Rowe, B.A., Schaffhauser, H., Rodriguez, D.E., Cambell, U.C., Daggett, L.P., Vernier, J.M. (2005). Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg Med Chem Lett, 15, 1565-1571.
88. Bonnefous, C., Vernier, J.M., Hutchinson, J.H., Gardner, M.F., Cramer, M., James, J.K., Rowe, B.A., Daggett, L.P., Schaffhauser, H., Kamenecka, T.M. (2005). Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype receptor. Bioorg Med Chem Lett, 15, 4354-4358.
89. Govek, S.P., Bonnefous, C., Hutchinson, J.H., Kamenecka, T., McQuiston, J., Pracitto, R., Zhao, L.X., Gardner, M.F., James, J.K., Daggett, L.P., Rowe, B.A., Schaffhauser, H., Bristow, L.J., Campbell, U.C., Rodriguez, D.E., Vernier, J.M. (2005). Benzazoles as allosteric potentiators of metabotropic glutamate receptor (mGluR2): efficacy in an animal model for schizophrenia. Bioorg Med Chem Lett, 15, 4068-4072.
90. Zhang, L., Rogers, B.N., Duplantier, A.J., McHardy, S.F., Efremov, I., Berke, H., Qian, W., Zhang, A.Q., Maklad, N., Candler, J., Doran, A.C., Lazzaro, J.T., Ganong, A.H. (2008). 3-(Imidazolylmethyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulators. Bioorg Med Chem Lett, 18, 5493-5496.
91. D'Alessandro, P.L., Corti, C., Roth, A., Ugolini, A., Sava, A., Montanari, D., Bianchi, F., Garland, S., Powney, B., Koppe, E.L., Rocheville, M., Osborne, G., Perez, P., De La Fuente, J., De Los Frailes, M., Smith, P.W., Branch, C., Nash, D., Watson, S.P. (2010). The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2. Bioorg Med Chem Lett, 20, 759-762.
92. Tresadern, G., Cid, J.M., Macdonald, G.J., Vega, J.A., de Lucas, A.I., Garcia, A., Matesanz, E., Linares, M.L., Oehlrich, D., Lavreysen, H., Biesmans, I., Trabanco, A.A. (2010). Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2-receptor. Bioorg Med Chem Lett, 20, 175-179.
93. Duplantier, A.J., Efremov, I., Candler, J., Doran, A.C., Ganong, A.H., Hass, J.A., Hanks, A.N., Kraus, K.G., Lazzaro, J.T., Lu, J., Maklad, N., McCarthy, S.A., O'Sullivan, T.J., Siuciak, J.A., Sprracklin, D.K., Zhang, L. (2009). 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: hit-to-lead and lead optimization. B ioorg Med Chem Lett, 19, 2524-2529.
94. Aghajanian, G.K., Marek, G.J. (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology, 36, 589-599.
95. Marek, G.J., Wright, R.A., Schoepp, D.D., Monn, J.A., Aghajanian, G.K. (2000). Physiological antagonism between 5-hydroxytryptamine 2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther, 292, 76-87.
96. Mateo, Z., Porter, J.T. (2007). Group II metabotropic glutamate receptors inhibit glutamate release at thalamocortical synapses in the developing somatosensory cortex. N euroscience, 146, 1062-1072.
97. Zhai, Y., George, C.A., Zhai, J., Nisenbaum, E.S., Johnson, M.P., Nisenbaum, L.K. (2003). Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology, 28, 45-52.
98. Kilbride, J., Huang, L.Q., Rowan, M.J., Anwyl, R. (1998). Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. E ur J Pharmacol, 356, 149-157.
99. 3H]LY354740 to recombinant and native metabotropic glutamate 2 and 3 receptors. J Neurochem, 94, 150-160.
100. 35S]GTP γ S binding. J Comp Neurol, 487, 15-27.
101. Conn, P.J., Battaglia, G., Marino, M.J., Nicoletti, F. (2005). Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci, 6, 787-798.
102. Lovinger, D.M., McCool, B.A. (1995). Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGluR2 or 3. J Neurophysiol, 73, 1076-1083.
103. 2+ channels in metabotropic glutamate receptor 2/3-dependent presynaptic long-term depression at nucleus accumbens synapses. J Neurosci, 22, 4346-4356.
104. Poisik, O., Raju, D.V., Verreault, M., Rodriquez, A., Abeniyi, O.A., Conn, P.J., Smith, Y. (2005). Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology, 49, 57-69.
105. Bradley, S.R., Marino, M.J., Wittmann, M., Rouse, S.T., Awad, H., Levey, A.I., Conn, P.J. (2000). Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J Neurosci, 20, 3085-3094.
106. Wittmann, M., Marino, M.J., Conn, P.J. (2002). Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J Pharmacol Exp Ther, 302, 433-441.
107. Guillery, R.W. (1995). Anatomical evidence concerning the role of the thalamus in corticocortical communication: a brief review. J Anat, 187, 583-592.
108. Sherman, S.M., Guillery, R.W. (1996). Functional organization of thalamocortical relays. J Neurophysiol, 76, 1367-1395.
109. Neto, F.L., Schadrack, J., Berthele, A., Zieglgansberger, W., Tolle, T.R., Castro-Lopes, J.M. (2000). Differential distribution of metabotropic glutamate receptor subtype mRNAs in the thalamus of the rat. Brain Res, 854, 93-105.
110. Alexander, G.M., Godwin, D.W. (2005). Presynaptic inhibition of corticothalamic feedback by metabotropic glutamate receptors. J Neurophysiol, 94, 163-175.
111. Turner, J.P., Salt, T.E. (2003). Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurons in vitro. Neuroscience, 122, 459-469.
112. Hermes, M.L., Kolaj, M. (2009). Activation of Pre-and Postsynaptic Group II Metabotropic Glutamate Receptors Reduce the Excitability of Midline Thalamic Neurons. Chicago: Society for Neuroscience. 2009 Neuroscience Meeting Planner.
113. Turner, J.P., Salt, T.E. (1999). Group III metabotropic glutamate receptors control corticothalamic synaptic transmission in the rat thalamus in vitro. J Physiol, 519, 2, 481-491.
114. Neugebauer, V., Zinebi, F., Russell, R., Gallagher, J.P., Shinnick-Gallagher, P. (2000). Cocaine and kindling alter the sensitivity of group II and group III metabotropic glutamate receptors in the central amygdala. J Neurophysiol, 84, 759-770.
115. Grueter, B.A., Winder, D.G. (2005). Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis. Neuropsychopharmacology, 30, 1302-1311.
116. Muly, E.C., Mania, I., Guo, J.-D., Rainnie, D.G. (2007). Group II metabotropic glutamate receptors in anxiety circuitry: correspondence of physiological response and subcellular distribution. J Comp Neurol, 505, 682-700.
117. Homayoun, H., Jackson, M.E., Moghaddam, B. (2005). Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol, 93, 1989-2001.
118. Homayoun, H., Moghaddam, B. (2008). Orbitofrontal cortex neurons as a common target for classic and glutamateric antipsychotic drugs. Proc Natl Acad Sci U S A, 105, 18041-18046.
119. Schaffhauser, H., Rowe, B.A., Morales, S., Chavez-Noriega, L.E., Yin, R., Jachec, C., Rao, S.P., Bain, G., Pinkerton, A.B., Vernier, J.-M., Bristow, L.J., Varney, M.A., Daggett, L.P. (2003). Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol, 64, 798-810.
120. Abi-Dargham, A. (2004). Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol, 7 (Suppl 1), S1-S5.
121. Rorick-Kehn, L.M., Johnson, B.G., Knitowski, K.M., Salhoff, C.R., Witkin, J.M., Perry, K.W., Griffey, K.I., Tizzano, J.P., Monn, J.A., McKinzie, D.L., Schoepp, D.D. (2007). In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology, 193, 121-136.
122. Cartmell, J., Perry, K.W., Salhoff, C.R., Monn, J.A., Schoepp, D.D. (2000). The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole3-acetic acid in the medial prefrontal cortex of the freely moving rat. J Neurochem, 75, 1147-1154.
123. Moghaddam, B., Adams, B.W. (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats. Science, 281, 1349-1352.
124. Lorrain, D.S., Baccei, C.S., Bristow, L.J., Anderson, J.J., Varney, M.A. (2003a). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience, 117, 697-706.
125. Swanson, C.J., Schoepp, D.D. (2003). A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann N Y Acad Sci, 1003, 309-317.
126. Lorrain, D.S., Schaffhauser, H., Campbell, U.C., Baccei, C.S., Correa, L.D., Rowe, B., Rodriquez, D.E., Anderson, J.J., Varney, M.A., Pinkerton, A.B., Vernier, J.M., Bristow, L.J. (2003b). Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology, 28, 1622-1632.
127. Fell, M.J., Svensson, K.A., Johnson, B.G., Schoepp, D.D. (2008). Evidence for the role of metabotropic glutamate (mGlu)2 but not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther, 326, 209-217.
128. Kim, J.H., Vezina, P. (2002). The mGlu2/3 receptor agonist LY379268 blocks the expression of locomotor sensitization by amphetamine. Pharmacol Biochem Behav, 73, 333-337.
129. Cartmell, J., Monn, J.A., Schoepp, D.D. (1999). The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther, 291, 161-170.
130. Cartmell, J., Monn, J.A., Schoepp, D.D. (2000). The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol, 400, 221-224.
131. Wadenberg, M.G., Hicks, P.B. (1999). The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? N eurosci Biobehav Rev, 23, 851-862.
132. Shannon, H.E., Rasmussen, K., Bymaster, F.P., Hart, J.C., Peters, S.C., Swedberg, M.D., Jeppesen, L., Sheardown, M.J., Sauerberg, P., Fink-Jensen, A. (2000). Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res, 42, 249-259.
133. Shekhar, A., Potter, W.Z., Lightfoot, J., Lienemann, J., Dube, S., Mallinckrodt, C., Bymaster, F.P., McKinzie, D.L., Felder, C.C. (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry, 165, 1033-1039.
134. Takamori, K., Hirota, S., Chaki, S., Tanaka, M. (2003). Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat. Life Sci, 73, 1721-1728.
135. Cartmell, J., Monn, J.A., Schoepp, D.D. (2000). Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology, 148, 423-429.
136. Rorick-Kehn, L., Perkins, E.J., Knitowki, K.M., Hart, J.C., Johnson, B.G., Schoepp, D.D., McKinzie, D.L. (2006). Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther, 316, 905-913.
137. Gewirtz, J.C., Marek, G.J. (2000). Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology, 23, 569-576.
138. Klodzinska, A., Bijak, M., Tokarski, K., Pilc, A. (2002). Group II mGlu receptor agonists inhibit behavioral and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav, 73, 327-332.
139. Uslaner, J.M., Smith, S.M., Huszar, S.L., Pachmerhiwala, R., Hinchliffe, R.M., Vardigan, J.D., Hutson, P.H. (2009). Combined administratino of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology (Berl), 206, 641-651.
140. Cartmell, J., Monn, J.A., Schoepp, D.D. (2000). Tolerance to the motor impairment, but not reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268. Naunyn Schmiedebergs Arch Pharmacol, 361, 39-46.
141. Imre, G., Fokkema, D.S., Ter Horst, G.J. (2006a). Subchronic administration of LY379268 does not modify ketamine-evoked behavior and neuronal activity in rats. Eur J Pharmacol, 544, 77-81.
142. Clark, M., Johnson, B.G., Wright, R.A., Monn, J.A., Schoepp, D.D. (2002). Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats. Pharmacol Biochem Behav, 73, 339-346.
143. Schreiber, R., Lowe, D., Voerste, A., De Vry, J. (2000). LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol, 388, R3-R4.
144. Imre, G., Salomons, A., Jongsma, M., Fokkema, D.S., Den Boer, J.A., Ter Horsts, G.J. (2006). Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviors and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav, 84, 392-399.
145. Satow, A., Maehara, S., Ise, S., Hikichi, H., Fukushima, M., Suzuki, G., Kimura, T., Tanak, T., Ito, S., Kawamoto, H., Ohta, H. (2008). Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide] amide]. J Pharmacol Exp Ther, 326, 577-586.
146. Winter, J.C., Eckler, J.R., Rabin, R.A. (2004). Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology, 172, 233-240.
147. Krystal, J.H., Abi-Saab, W., Perry, E., D'Souza, D.C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., Breier, A. (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subject. P sychopharmacology (Berl), 179, 303-309.
148. Spinelli, S., Ballard, T., Gatti-McArthur, S., Richards, G.J., Kapps, M., Woltering, T., Wichmann, J., Stadler, H., Feldon, J., Pryce, C.R. (2005). Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology, 179, 292-302.
149. Greco, B., Invernizzi, R.W., Carli, M. (2005). Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGlu(2/3) receptor agonist LY379268. Psychopharmacology, 179, 68-76.
150. Amitai, N., Markou, A. (2010). Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats. Eur J Pharmacol, 639, 67-80. [Epubl]: PMID: 20371228.
151. Harich, S., Gross, G., Bespalov, A. (2007). Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl), 192, 511-519.
152. Spooren, W.P., Gasparini, F., van der Putten, H., Koller, M., Nakanishi, S., Kuhn, R. (2000). Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol, 397, R1-R2.
153. Woolley, M.L., Pemberton, D.J., Bate, S., Corti, C., Jones, D.N. (2008). The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl), 196, 431-440.
154. Fell, M.J., Johnson, B.G., Falcone, J.F., Perry, K.W., Barth, V.N., Rash, K.S., Monn, J.A., Schoepp, D.D., McKinzie, D.L., Nelson, D.L., Marek, G.J., Svensson, K.A. (2008). In vivo Neurochemical and Behavioral Evidence for Lack of direct Dopamine D2 Receptor Mediated Actions of mGluR2/3 Agonists, Program No. 155.7. Washington, DC: Society for Neuroscience, 2008 Neuroscience Meeting Planner. Online.
155. Karlsson, R.M., Tanaka, K., Heilig, M., Holmes, A. (2008). Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonists. Biol Psychiatry, 64, 810-814.
156. Chartoff, E.H., Heusner, C.L., Palmiter, R.D. (2005). Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology, 30, 1324-1333.
157. Bridges, T.M., Lindsley, C.W. (2008). G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol, 19, 530-541.
158. May, L.T., Leach, K., Sexton, P.M., Christopoulos, A. (2007). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol, 47, 1-51.
159. Hackler, E.A., Byun, N.E., Jones, C.K., Williams, J.M., Baheza, R., Sengupta, S., Grier, M.D., Avison, M., Conn, P.J., Gore, J.C. (2010). Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks the phencyclidine-induced hyperlocomotion and brain activation. Neuroscience, 168, 209-218. [Epub] PMID: 20350588.
160. Patil, S.T., Zhang, L., Martenyi, F., Lowe, S.L., Jackson, K.A., Andreev, B.V., Avedisova, A.S., Bardenstein, L.M., Gurovich, I.Y., Morozova, M.A., Mosolov, S.N., Neznanov, N.G., Reznik, A.M., Smulevich, A.B., Tochilov, V.A., Johnson, B.G., Monn, J.A., Schoepp, D.D. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med, 13, 1102-1107.
161. Kinon, B.J., Zhang, L., Millen, B.A., Osuntokun, O.O., Williams, J.E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., Jarkova, N., and the HBBI Study Group (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia phrenia. J Clin Psychopharmacol, 31 (3), 349-355.
162. Zhang, C., Marek, G.J. (2007). Group III metabotropic glutamate receptor agonists selectively suppress excitatory synaptic currents in the rat prefrontal cortex induced by 5-hydroxytryptamine 2A receptor activation. J Pharmacol Exp Ther, 320, 437-447.
163. Kew, J.N., Ducarre, J.M., Pflimlin, M.C., Mutel, V., Kemp, J.A. (2001). Activity-dependent presynaptic autoinhibition by group II metabotropic glutamate receptors at the perforant path inputs to the dentate gyrus and CA1. Neuropharmacology, 40, 20-27.